Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G807-20. doi: 10.1152/ajpgi.00195.2010. Epub 2010 Jul 1.
Colorectal cancer remains a major cause of morbidity and mortality in the United States. The advent of molecular therapies targeted against specific, stereotyped cellular mutations that occur in this disease has ushered in new hope for treatment options. However, key questions regarding optimal dosing schedules, dosing duration, and patient selection remain unanswered. In this review, we describe how recent advances in molecular imaging, specifically optical molecular imaging with fluorescent probes, offer potential solutions to these questions. We begin with an overview of optical molecular imaging, including discussions on the various methods of design for fluorescent probes and the clinically relevant imaging systems that have been built to image them. We then focus on the relevance of optical molecular imaging to colorectal cancer. We review the most recent data on how this imaging modality has been applied to the measurement of treatment efficacy for currently available as well as developmental molecularly targeted therapies. We then conclude with a discussion on how this imaging approach has already begun to be translated clinically for human use.
结直肠癌仍然是美国发病率和死亡率的主要原因。针对这种疾病中发生的特定、定型细胞突变的分子治疗方法的出现,为治疗选择带来了新的希望。然而,关于最佳剂量方案、剂量持续时间和患者选择的关键问题仍未得到解答。在这篇综述中,我们描述了分子成像的最新进展,特别是荧光探针的光学分子成像,如何为这些问题提供潜在的解决方案。我们首先概述了光学分子成像,包括对荧光探针设计的各种方法以及为成像而构建的临床相关成像系统的讨论。然后,我们将重点放在光学分子成像与结直肠癌的相关性上。我们回顾了最近的数据,说明这种成像方式如何应用于目前可用的以及正在开发的分子靶向治疗的疗效测量。最后,我们讨论了这种成像方法如何已经开始为人类临床应用而转化。